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ABSTRACT
Although the ﬁrst reports on extended-spectrum b-lactamase (ESBL)-producing isolates in long-term-
care facilities (LTCFs) appeared 10 years ago, there are still scanty data on this topic. A long-term survey
starting in 1993 by the microbial laboratories of the Assistance Publique Hopitaux de Paris and covering
21 000 beds, 7000 of them in LTCFs, indicated that the incidence of ESBL-producing isolates ⁄ 1000
hospitalisation days in LTCFs increased from 0.07 in 1996 to 0.28 in 2005. Escherichia coli accounted for
80% of ESBL-positive isolates in 2005, whereas it accounted for <45% in 2001. This rise in E. coli with
ESBLs reﬂected clonal spread, as found elsewhere, with CTX-M types now the predominant enzyme
types.
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INTRODUCTION
Articles focusing on extended-spectrum b-lactam-
ase (ESBL)-producing Enterobacteriaceae isolates
in long-term-care facilities (LTCFs) or nursing
homes are few in number [1–9]. The present
article is, to our knowledge, the ﬁrst to report a
long-term survey of ESBL-producing isolates
identiﬁed in clinical specimens sampled from
patients of LTCFs.
The microbiologists of the Assistance Publique
Hoˆpitaux de Paris (AP-HP), which includes 47
hospitals with a total of 21 000 beds, have anal-
ysed the ESBL-producing Enterobacteriaceae iso-
lates collected at 39 short-term-care facilities
(STCFs, 14 000 beds) and the eight LTCFs (7000
beds) during 2-month periods of each year since
1993. ESBL-producing Enterobacteriaceae isolates
were detected using the double-disk synergy test
[10] as routinely applied in AP-HP microbiology
laboratories and interpreted according to the
recommendations of the French Antibiotic Com-
mittee [11]. Clinical and antibiotic susceptibility
data were also collected for each isolate.
RESULTS
Incidence of ESBL-producing
Enterobacteriaceae in AP-HP STCFs and LTCFs
Fig. 1 shows the total number of ESBL-producing
Enterobacteriaceae isolates collected each year
over the study period and the incidence density
per 1000 hospitalisation days (HD) in all AP-HP
STCFs and LTCFs from 1996 to 2005. The total
number of ESBL-producing Enterobacteriaceae
isolates was four times higher in 2005 than in
1996, while the incidence density was globally
stable until 2001 in both STCFs (between 0.15 and
0.2 ⁄ 1000 HD) and LTCFs (between 0.05 and
0.09 ⁄ 1000 HD). It then increased gradually to
reach 0.35 ⁄ 1000 HD in STCFs in 2005, whereas it
suddenly increased in LTCFs in 2003, reaching
0.28 ⁄ 1000 HD in 2006.
Differences between ESBL-producing
Enterobacteriaceae isolates from STCFs and
LTCFs
Between 2001 and 2005, the proportions of
Klebsiella oxytoca, Proteus mirabilis, Enterobacter
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cloacae and Klebsiella pneumoniae with ESBLs were
£10%, in AP-HP LTCFs (Fig. 2). The proportion of
Enterobacter aerogenes isolates with ESBLs signiﬁ-
cantly decreased from 25% to 5%, whereas that of
Escherichia coli isolates dramatically increased,
accounting for 80% of ESBL-producing Entero-
bacteriaceae from LTCFs by 2005. The proportion
of E. coli isolates among ESBL producers also
increased between 2001 and 2005 in STCFs
(Fig. 3), whereas that of E. aerogenes isolates
decreased, and those of K. oxytoca, P. mirabilis and
K. pneumoniae isolates remained stable. However,
the species proportions were different between
STCFs and LTCFs, and in 2005, the proportions
were 50% and 80%, respectively for E. coli, 25%
and 10%, respectively, for K. pneumoniae, and
12% and 5%, respectively, for E. cloacae. Other
differences were observed between LTCFs and
STCFs. The ﬁrst difference concerned the delay
between patient admission and the time for ESBL
positivity. This delay exceeded 30 days for the
great majority of the patients hospitalised in
LTCFs between 2003 and 2005, whereas an
ESBL-producing isolate was obtained within the
ﬁrst 2 days of hospitalisation for a third of the
ESBL-positive patients in STCFs. This feature was
particularly apparent for E. coli; 100 out of the 280
ESBL-positive isolates collected between 2003 and
2005 in STCFs were isolated within the ﬁrst
2 days of hospitalisation. The second difference
concerned the types of clinical specimen. In
LTCFs, 89% of the isolates were from urine,
whereas this proportion was only 50% in STCFs,
where 30% of ESBL producers were isolated from
deep specimens (blood, pus and the lower respi-
ratory tract). The third difference concerned
antibiotic susceptibility; the LTCF isolates were
less often susceptible to quinolones than those
from STCFs, with 5% vs. 32% being susceptible to
ciproﬂoxacin (Table 1).
Molecular epidemiology of ESBL-producing
E. coli isolates in AP-HP LTCFs
In 2001 and 2002, i.e., before the general increase
in ESBL-producing isolates in the AP-HP LTCFs,
one of these facilities, a 650-bed long-term-care
hospital—referred to as ‘SP’—was confronted
with the emergence and spread of three virulent
clonally related strains of E. coli producing CTX-
M-15 enzyme [6]. The three strains, which
displayed the same randomly ampliﬁed polymor-
phic DNA (RAPD) proﬁle, were resistant to
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Fig. 2. Prevalence (%) of extended-spectrum b-lactamase-
producing isolates by species in Assistance Publique
Hoˆpitaux de Paris long-term-care facilities (2001–2005).
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Fig. 3. Prevalence (%) of extended-spectrum b-lactamase-
producing isolates by species in Assistance Publique
Hoˆpitaux de Paris short-term-care facilities (2001–2005).
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Fig. 1. Incidence density ⁄ 1000 hospitalisation days of
extended-spectrum b-lactamase-producing isolates in all
Assistance Publique Hoˆpitaux de Paris (AP-HP) settings,
in AP-HP short-term-care facilities and AP-HP long-term-
care facilities (1996–2005). The number of isolates collected
each year is indicated at the bottom.
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ﬂuoroquinolones and susceptible to co-trimoxaz-
ole, but differed from each other in their amino-
glycoside and tetracycline susceptibilities. One
lineage, which was ﬁrst isolated on 2 October
2001, was resistant to aminoglycosides, except for
gentamicin, and was then called GEN S. The
second lineage, which emerged 22 days later in
October 2001, was resistant to all aminoglycosides
and was called GEN R. The third lineage, which
emerged in April 2002, was susceptible to amino-
glycosides and was called AMG S. Strains GEN S
and AMG S spread into the different units and
subunits of the LTCF, whereas strain GEN R
spread only in the unit where it was ﬁrst isolated.
Overall, during the study period (October 2001 to
October 2002), 87 new patients had urinary tract
colonisation or infection due to strain GEN S,
while there were 12 episodes due to strain GEN R
and 13 due to strain AMG S. All three clonal ESBL
producers were shown to belong to the phyloge-
netic group B2, which is one of the two predom-
inant groups observed among extra-intestinal
pathogenic E. coli isolates (the other group being
D) and harbours the same virulence factor genes.
Interestingly, the number of virulence factor
genes was low, at just three (aer, fuyA and irp2),
which is uncommon for pathogenic E. coli strains
from phylogenetic group B2, although apparently
common among those that are resistant to ﬂuor-
oquinolones [12–14]. As shown in Fig. 4, the
emergence and spread of the lineages resulted
in an increased percentage of E. coli isolates not
susceptible to ﬂuroquinolones and ceftriaxone,
although still susceptible to co-trimoxazole. This
feature was accompanied by a decrease in the
consumption of ﬂuroquinolones, an increase in
that of co-trimoxazole, but no change in that of
ceftriaxone (Fig. 4).
Kassis-Chikhani et al. [9] described a similar
outbreak in one of the three long-term-care units of
the AP-HP STCF, referred to as ‘TN’. The index
case was detected in October 2001. Subsequently,
26 among the 47 patients in that unit were colon-
ised or infected, over a period of 27 months, by a
phylogenetic group B2 strain that produced the
CTX-M-15 ESBL. Once again, this had very few
virulence factor genes, and was resistant to ﬂuor-
oquinolones but susceptible to co-trimoxazole.
The curve of Fig. 1 clearly shows that more
than the two AP-HP LTCFs TN and SP reported
ESBL-producing isolates in 2005. To obtain more
insight into the wider distribution of ESBL-pro-
ducing isolates, especially E. coli, it was decided
to type the E. coli isolates collected in 2005 by
RAPD, as previously described [6]. Some exam-
ples of the results are presented in Figs 5 and 6, in
order to illustrate the general features of the ESBL
producers from LTCFs in Paris. The 14 ESBL-
producing E. coli isolates from the LTCF CF
(Fig. 5) displayed ﬁve distinct proﬁles, two com-
prising single isolates and three corresponding to
clusters: cluster 1 with three isolates, cluster 2
with seven isolates, and cluster 3 with two iso-
lates. For the LTCF CR (Fig. 6), three distinct
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Fig. 4. Consumption of ﬂuoroquinolones (m), ceftriaxone
(d), and co-trimoxazole (·), expressed as the deﬁned daily
doses (DDDs) per 1000 hospital days in the long-term-care
facility SP and the proportion of urinary Escherichia coli
isolates resistant to these antibiotics in 2000, 2001 and 2002
[6]. The bars represent data for E. coli isolates not suscep-
tible to ﬂuoroquinolones (bars), ceftriaxone (striped bars)
and co-trimoxazole (grey bars).
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Fig. 5. Randomly ampliﬁed polymorphic DNA proﬁles of
14 extended-spectrum b-lactamase-producing Escherichia
coli isolates from the long-term-care facilities CF (east–
southern suburb of Paris).
Numbers at the top correspond to the proﬁle type.
M, weight marker; NC, negative control.
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proﬁles were displayed among the14 ESBL-pro-
ducing E. coli isolates collected there, two of them
being very close to (proﬁles 1 and 1¢ in Fig. 6) but
clearly distinguishable from the third proﬁle
(proﬁle 2). Interestingly, proﬁles 1 and 1¢ were
very close, or identical, to those of the clonal
strains of 2001 and 2002 in LTCF SP (C in Fig. 6 ),
and the long-term-care unit of STCF TN (B in
Fig. 6).
RAPD proﬁles were available for the ESBL-
producing E. coli isolates from six of the eight AP-
HP LTCFs. On the basis of the global analysis of
these proﬁles, it was observed that: (i) clonal
strains were more common than unique strains in
the AP-HP LTCFs; (ii) the clonal strains in LTCFs
SP and TN in 2001 were probably the same strain;
and (iii) this strain was still present in 2005 in six
AP-HP LTCFs.
Characterisation of the ESBL produced by
Entrobacteriacae isolates in AP-HP LTCFs
The ESBLs produced by the Enterobacteriaceae in
LTCFs CF and CR in 2005 were molecularly
characterised [6,15]. All producers from facility
CF were E. coli, whereas they also included other
enterobacterial species in LTCF CR (Table 2). Ten
of the 14 E. coli isolates from facility CF produced
CTX-M-15 b-lactamase, as did 13 of 14 E. coli
isolates from CR. This b-lactamase was also found
in the Enterobacter sakazakii isolate identiﬁed in
LTCF CR (Table 2). Of the four remaining E. coli
isolates from LTCF CF, two were not conﬁrmed as
ESBL producers and single representatives
produced the b-lactamases CTX-M 17 ⁄ 18 and
TEM-14 ⁄ 120, respectively. The last E. coli isolate
from LTCF CR produced SHV-12, as did two
E. cloacae isolates and one K. pneumoniae isolate,
whereas the sole Serratia marcescens isolate pro-
duced SHV-5.
M 1 1 1 1’ 1 1 2 1’ 1’ 1’1 1 1 1 A 1” B 1’C 1’ NC
Fig. 6. Randomly ampliﬁed polymorphic DNA proﬁles of
14 extended-spectrum b-lactamase-producing Escherichia
coli isolates for the long-term-care facilities (LTCFs) CR
(northern suburb of Paris) and for known epidemic strains
A, B and C. Numbers at the top correspond to the types of
proﬁle. (A) LTCF SP current epidemic strain. (B) LTCF TN
2001 epidemic strain. (C) LTCF SP 2001 epidemic strain. M,
weight marker, NC, negative control.
Table 1. Antibiotic susceptibility of extended-spectrum
b-lactamase-producing isolates by location (2003–2005)
Antibiotic
Total no. of isolates (%
susceptible to antibiotic)
LTCF STCF
Gentamicin 268 (63) 726 (42)
Tobramycin 244 (36) 713 (24)
Amikacin 262 (58) 728 (56.5)
Nalidixic acid 258 (4) 699 (21.7)
Ciproﬂoxacin 250 (5) 701 (32.5)
Imipenem 259 (98) 727 (98.2)
LTCF, long-term-care facility; STCF, short-term-care
facility.
Table 2. Distribution of extended-spectrum b-lactamase (ESBL)-producing isolates and ESBL type among species in two
Assistance Publique Hoˆpitaux de Paris long-term-care facilities (LTCFs) in 2005
Species
LTCF CF (east-south suburb) LTCF CR (north suburb)
No. ESBL type (isolate no.) No. ESBL type (isolate no.)
Escherichia coli 14 CTX-M-15 (10) 14 CTX-M-15 (13)
CTX-M-17 ⁄ 18 (1) SHV-12 (1)
TEM-14 ⁄ 120 (1)
Non-BLSE (2)
Enterobacter cloacae – 2 SHV-12 (2)
Serratia marcescens – 1 SHV-5 (1)
Enterobacter sakazakii – 1 CTX-M-15 (1)
Klebsiella pneumoniae – 1 SHV-12 (1)
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DISCUSSION
The long-term survey (1993–2005) performed by
the Colle´giale de Bacte´riologie-Virologie-Hygie`ne
Hospitalie`re of AP-HP made it possible to mon-
itor a clear increase in ESBL-producing isolates of
E. coli and the stability over time of those of
K pneumoniae, independently of the care facility
type. These results are very similar to those found
by Romero et al. [5], who also carried out a long-
term survey in Seville (1995–2003). These authors
observed an increase in the frequency of ESBL-
producing isolates of E. coli and a stable rate of
ESBL-producing K. pneumoniae isolates in the area
served by the university hospital Virgen Macare-
na located in the North of Seville (Spain). This
mixture of change and stability concerned both
inpatients in different wards of the university
hospital and in a nearby chronic-care hospital,
and outpatients. The increase in ESBL-producing
E. coli isolates started in 1999 for inpatients and in
2000 for outpatients, 1–2 years before that in the
AP-HP hospitals.
By typing the ESBL-producing E. coli isolates
collected by the AP-HP LTCFs, we have shown
that clonal groups are common across these
facilities. Although the literature concerning
ESBL-producing isolates in LCTFs or nursing
homes is limited, some of the published articles
mention the clonal relatedness of the ESBL-pro-
ducing E. coli isolates collected in these medical
centres [2–5]. These data are summarised in
Table 3. Therefore, the most original point dem-
onstrated by the study performed at AP-HP is the
persistence of the same strain of ESBL-producing
E. coli over a long period of time in the same
LTCF, and the presence of this strain in different
LCTFs at the same time, although the LTCFs
concerned are distant from one another. Although
this strain belonged to phylogenetic group B2, it
harboured very few virulence factor-encoding
genes. This latter feature might explain why
bacteraemias due to this strain were rare in the
patients of the AP-HP LTCFs. Nevertheless, this
strain was resistant to amoxycillin, ceftriaxone
and ﬂuoroquinolones, antibiotics that are widely
used to treat infections in elderly people. Thus,
antibiotic selection pressure and the fact that it is
very difﬁcult to implement isolation precautions
in centres caring for elderly patients may both
explain the persistence and the spread of this type
of strain in LTCFs.
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